The anti-tumor activity of a neutralizing nanobody targeting leptin receptor in a mouse model of melanoma.

PLoS One · 2014 · PMC3938505 · PMID 24587106

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Leprb, the long-form leptin receptor, showed a trend of increase ( Fig. 5B ) probably indicating an adaptive response to the antagonism to LepR.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.